Voyager Therapeutics Presents Data for Second-Generation, TRACER-Generated Capsids and CNS Gene Therapy Programs Advancing Toward Clinical Trials at the ASGCT Annual Meeting
$VYGR
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
- Translational potential of TRACER-derived AAV capsids demonstrated by data across multiple species (murine, porcine, multiple NHPs, human cells) and receptor binding
- Preclinical safety and efficacy demonstrated in Alzheimer's disease and ALS gene therapies; low IV doses provided broad CNS biodistribution and robust transduction of key cell types